Q1 EPS Estimate for iRhythm Technologies Boosted by Analyst

iRhythm Technologies, Inc. (NASDAQ:IRTC) – William Blair boosted their Q1 2025 EPS estimates for shares of iRhythm Technologies in a report released on Thursday, October 31st. William Blair analyst M. Kaczor now expects that the company will post earnings of ($0.65) per share for the quarter, up from their prior forecast of ($0.92). The consensus estimate for iRhythm Technologies’ current full-year earnings is ($3.07) per share. William Blair also issued estimates for iRhythm Technologies’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.40) EPS and Q4 2025 earnings at ($0.29) EPS.

Several other equities research analysts have also weighed in on the company. JPMorgan Chase & Co. decreased their target price on iRhythm Technologies from $133.00 to $100.00 and set an “overweight” rating on the stock in a report on Friday, August 2nd. Needham & Company LLC cut their target price on shares of iRhythm Technologies from $119.00 to $96.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on iRhythm Technologies in a report on Friday, October 4th. They issued a “neutral” rating and a $78.00 price objective on the stock. Canaccord Genuity Group increased their target price on shares of iRhythm Technologies from $122.00 to $137.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Oppenheimer reduced their price objective on shares of iRhythm Technologies from $165.00 to $145.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $108.50.

iRhythm Technologies Trading Up 6.4 %

Shares of IRTC stock opened at $86.68 on Monday. iRhythm Technologies has a fifty-two week low of $55.92 and a fifty-two week high of $124.11. The company has a quick ratio of 6.12, a current ratio of 6.27 and a debt-to-equity ratio of 9.00. The stock has a 50-day simple moving average of $69.85 and a 200 day simple moving average of $84.46. The stock has a market capitalization of $2.71 billion, a P/E ratio of -17.84 and a beta of 1.23.

iRhythm Technologies (NASDAQ:IRTC) last announced its earnings results on Wednesday, October 30th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.71). The company had revenue of $147.54 million during the quarter, compared to the consensus estimate of $146.69 million. iRhythm Technologies had a negative net margin of 26.90% and a negative return on equity of 120.86%. The business’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.89) EPS.

Hedge Funds Weigh In On iRhythm Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Westfield Capital Management Co. LP bought a new stake in iRhythm Technologies in the first quarter valued at $58,311,000. Champlain Investment Partners LLC grew its holdings in shares of iRhythm Technologies by 104.1% in the 1st quarter. Champlain Investment Partners LLC now owns 575,800 shares of the company’s stock worth $66,793,000 after purchasing an additional 293,710 shares during the last quarter. First Light Asset Management LLC grew its holdings in shares of iRhythm Technologies by 176.8% in the 1st quarter. First Light Asset Management LLC now owns 420,892 shares of the company’s stock worth $48,823,000 after purchasing an additional 268,829 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in iRhythm Technologies by 5.9% during the 2nd quarter. Mackenzie Financial Corp now owns 1,428,324 shares of the company’s stock valued at $153,745,000 after purchasing an additional 80,091 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in iRhythm Technologies by 14.5% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 511,905 shares of the company’s stock valued at $59,381,000 after purchasing an additional 64,755 shares during the last quarter.

Insider Transactions at iRhythm Technologies

In related news, CFO Brice Bobzien sold 1,372 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $70.34, for a total value of $96,506.48. Following the completion of the transaction, the chief financial officer now directly owns 24,428 shares in the company, valued at approximately $1,718,265.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other iRhythm Technologies news, CFO Brice Bobzien sold 1,372 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $70.34, for a total value of $96,506.48. Following the sale, the chief financial officer now owns 24,428 shares of the company’s stock, valued at $1,718,265.52. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Abhijit Y. Talwalkar acquired 6,664 shares of iRhythm Technologies stock in a transaction dated Monday, November 4th. The shares were acquired at an average cost of $75.16 per share, with a total value of $500,866.24. Following the completion of the acquisition, the director now directly owns 18,941 shares in the company, valued at $1,423,605.56. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.68% of the stock is owned by insiders.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.